Skip to main navigation Skip to search Skip to main content

Correction to: Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors (Acta Neuropathologica, (2024), 148, 1, (68), 10.1007/s00401-024-02836-5)

  • Jelena Jotanovic
  • , Henning Bünsow Boldt
  • , Mark Burton
  • , Marianne Skovsager Andersen
  • , Daniel Bengtsson
  • , Thomas Olsson Bontell
  • , Bertil Ekman
  • , Britt Edén Engström
  • , Ulla Feldt-Rasmussen
  • , Ansgar Heck
  • , Antonia Jakovcevic
  • , Jens Otto L. Jørgensen
  • , Ivana Kraljevic
  • , Jacek Kunicki
  • , John R. Lindsay
  • , Marco Losa
  • , Paul Benjamin Loughrey
  • , Dominique Maiter
  • , Maria Maksymowicz
  • , Emilija Manojlovic-Gacic
  • Jens Pahnke, Stephan Petersenn, Maria Petersson, Vera Popovic, Oskar Ragnarsson, Åse Krogh Rasmussen, Zita Reisz, Wolfgang Saeger, Camilla Schalin-Jäntti, David Scheie, Maria Rosa Terreni, Olli Tynninen, Ben Whitelaw, Pia Burman, Olivera Casar-Borota*
*Corresponding author for this work
  • Uppsala University
  • University of Southern Denmark
  • Linköping University
  • Kalmar County Hospital
  • University of Gothenburg
  • Sahlgrenska University Hospital
  • University of Copenhagen
  • University of Oslo
  • University of Zagreb
  • Aarhus University
  • Maria Sklodowska-Curie Institute of Oncology
  • Royal Victoria Hospital Belfast
  • Vita-Salute San Raffaele University
  • Queen's University Belfast
  • Université catholique de Louvain
  • University of Belgrade
  • ENDOC Center for Endocrine Tumors
  • University of Duisburg-Essen
  • Karolinska Institutet
  • King’s College Hospital
  • University of Hamburg
  • Helsinki University Central Hospital
  • University of Helsinki
  • Lund University

Research output: Contribution to journalComment/debate/note

Abstract

In the original publication of this article, upper and lower part of Table 2 was incorrectly formatted. The incorrect and correct version of Table 2 are shown in this correction article. The original article has been corrected. Relevant significantly enriched gene sets associated with the DMPs that differed between aggressive and metastatic PitNETs in the first surgery specimens (upper table) and in the entire cohort (lower table) Hypermethylated and positive enriched in PC pval padj NES size KEGG cell adhesion molecules CAMS 6.26E-07 5.63E-05 1.65 122 KEGG axon guidance 6.51E-07 5.63E-05 1.65 122 KEGG pathways in cancer 1.43E-06 8.24E-05 1.44 313 KEGG neuroactive ligand receptor interaction 6.39E-06 0.00028 1.44 249 KEGG focal adhesion 7.16E-05 0.0015 1.44 191 KEGG adherens junction 8.97E-05 0.0017 1.64 67 KEGG calcium signaling pathway 0.00025 0.0039 1.40 166 KEGG leukocyte transendothelial migration 0.0019 0.019 1.43 108 KEGG ECM receptor interaction 0.0019 0.019 1.49 83 KEGG gap junction 0.0063 0.036 1.40 83 KEGG axon guidance 1.60E-06 0.00028 1.53 122 KEGG calcium signaling pathway 3.22E-06 0.00028 1.44 166 KEGG neuroactive ligand receptor interaction 0.00010 0.0045 1.31 249 KEGG regulation of actin cytoskeleton 0.00013 0.0045 1.34 197 KEGG MAPK signaling pathway 0.00030 0.0066 1.29 251 KEGG cell adhesion molecules cams 0.0018 0.035 1.33 122 KEGG ECM receptor interaction 0.0034 0.049 1.36 83 KEGG Wnt signaling pathway 0.0052 0.064 1.27 145 KEGG Hedgehog signaling pathway 0.0057 0.064 1.40 55 KEGG leukocyte transendothelial migration 0.011 0.10 1.28 108 Relevant significantly enriched gene sets associated with the DMPs that differed between aggressive and metastatic PitNETs in the first surgery specimens (upper part of the table) and in the entire cohort (lower part of the table) Hypermethylated and positive enriched in PC pval padj NES size KEGG Cell adhesion molecules CAMS 6.26E-07 5.63E-05 1.65 122 KEGG Axon guidance 6.51E-07 5.63E-05 1.65 122 KEGG Pathways in cancer 1.43E-06 8.24E-05 1.44 313 KEGG Neuroactive ligand receptor interaction 6.39E-06 0.00028 1.44 249 KEGG Focal adhesion 7.16E-05 0.0015 1.44 191 KEGG Adherens junction 8.97E-05 0.0017 1.64 67 KEGG Calcium signaling pathway 0.00025 0.0039 1.40 166 KEGG Leukocyte transendothelial migration 0.0019 0.019 1.43 108 KEGG ECM receptor interaction 0.0019 0.019 1.49 83 KEGG Gap junction 0.0063 0.036 1.40 83 Hypermethylated and positive enriched in PC pval padj NES size KEGG Axon guidance 1.60E-06 0.00028 1.53 122 KEGG Calcium signaling pathway 3.22E-06 0.00028 1.44 166 KEGG Neuroactive ligand receptor interaction 0.00010 0.0045 1.31 249 KEGG Regulation of actin cytoskeleton 0.00013 0.0045 1.34 197 KEGG MAPK signaling pathway 0.00030 0.0066 1.29 251 KEGG Cell adhesion molecules cams 0.0018 0.035 1.33 122 KEGG ECM receptor interaction 0.0034 0.049 1.36 83 KEGG Wnt signaling pathway 0.0052 0.064 1.27 145 KEGG Hedgehog signaling pathway 0.0057 0.064 1.40 55 KEGG Leukocyte transendothelial migration 0.011 0.10 1.28

Original languageEnglish
Article number4
JournalActa Neuropathologica
Volume149
Issue number1
DOIs
Publication statusPublished - Jun 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Correction to: Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors (Acta Neuropathologica, (2024), 148, 1, (68), 10.1007/s00401-024-02836-5)'. Together they form a unique fingerprint.

Cite this